Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
@article{Boden2011NiacinIP, title={Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.}, author={W. Boden and J. Probstfield and T. Anderson and B. Chaitman and Patrice Desvignes-Nickens and K. Koprowicz and R. Mcbride and K. Teo and W. Weintraub}, journal={The New England journal of medicine}, year={2011}, volume={365 24}, pages={ 2255-67 } }
BACKGROUND
In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk.
METHODS
We randomly assigned eligible patients to receive extended-release niacin, 1500 to… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
The purpose of this study is to determine whether raising "good cholesterol" with a drug
based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent… Expand
Conditions | Atherosclerosis, Cardiovascular Diseases, Cerebrovascular Accident, (+3 more) |
---|---|
Intervention | Drug |
Paper Mentions
Interventional Clinical Trial
The primary objective of this study is to generate preliminary data on the effects of a
short-term diet of either fast food or Mediterranean type diet on HDL and microbiota… Expand
Conditions | Diet Modification, HDL, Inflammation |
---|---|
Intervention | Other |
Observational Clinical Trial
Aortic valve stenosis (AVS), the most common form of valve disease in the western world,
afflicts more than 1 million individuals in North America [1] and the burden of AVS is high… Expand
Conditions | Heterozygous Familial Hypercholesterolemia |
---|
Interventional Clinical Trial
Treatment using statin has been decreased the risk of cardiovascular events in pre-dialysis
CKD population. Supplementation with omega-3 fatty acid (FA) lowers the risk of… Expand
Conditions | Chronic Kidney Disease |
---|---|
Intervention | Drug |
News Article
2,229 Citations
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
- Medicine
- The New England journal of medicine
- 2015
- 852
- PDF
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
- Medicine
- The New England journal of medicine
- 2012
- 1,536
- PDF
Effects of extended-release niacin with laropiprant in high-risk patients.
- Medicine
- The New England journal of medicine
- 2014
- 1,014
- PDF
Combination therapy in dyslipidemia: where are we now?
- Medicine
- Atherosclerosis
- 2014
- 46
- Highly Influenced
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
- Medicine
- Cholesterol
- 2012
- 49
- PDF
Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
- Medicine
- Current Diabetes Reports
- 2018
- 2
Niacin in cardiovascular patients receiving statins.
- Medicine
- The New England journal of medicine
- 2012
- 4
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- Medicine
- The New England journal of medicine
- 2017
- 465
- PDF
References
SHOWING 1-10 OF 24 REFERENCES
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in M
- Medicine
- American heart journal
- 2011
- 40
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome wit
- Medicine
- American heart journal
- 2011
- 138
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
- Medicine
- The New England journal of medicine
- 2001
- 1,435
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
- Medicine
- Circulation
- 2004
- 721
- PDF
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.
- Medicine
- Atherosclerosis
- 2010
- 269
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- Medicine
- Journal of the American College of Cardiology
- 2010
- 221
Prevalence of conventional risk factors in patients with coronary heart disease.
- Medicine
- JAMA
- 2003
- 512
- PDF